SCHEMBL7939889

SCHEMBL7939889

Cc1cc(C(=O)Nc2cccc(CNc3cccnc3N)c2)no1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 6/20 0.66
SMN1; SMN2 Q16637 3/20 0.53
ALDH1A1 P00352 2/20 0.53
USP2 O75604 1/20 0.53
HSD17B10 Q99714 1/20 0.52
NPC1 O15118 3/20 0.47
RAB9A P51151 3/20 0.47
TP53 P04637 2/20 0.47
NFKB1 P19838 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47
TSHR P16473 1/20 0.47
CYP1A2 P05177 2/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C19 P33261 1/20 0.46
GLA P06280 1/20 0.46
HTT P42858 1/20 0.46
ACKR3 P25106 1/20 0.45
LMNA P02545 1/20 0.44
PTGS2 P35354 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7940971 0.86 BACE1 (0.64) BACE1
SCHEMBL7932768 0.86 BACE1 (0.49) BACE1SMN1; SMN2ALDH1A1USP2HSD17B10
SCHEMBL7942892 0.86 BACE1 (0.61) BACE1NPC1RAB9ATP53GLA
SCHEMBL7944660 0.85 BACE1 (0.62) BACE1SMN1; SMN2ALDH1A1NPC1RAB9A
SCHEMBL7933424 0.85 BACE1 (0.73) BACE1SMN1; SMN2ALDH1A1LMNA
SCHEMBL7941334 0.84 BACE1 (0.78) BACE1SMN1; SMN2ALDH1A1NPC1RAB9A
SCHEMBL7945350 0.83 BACE1 (0.47) BACE1SMN1; SMN2ALDH1A1USP2HSD17B10
SCHEMBL7939893 0.83 BACE1 (0.60) BACE1SMN1; SMN2ALDH1A1NPC1RAB9A
SCHEMBL7942031 0.83 BACE1 (0.65) BACE1
SCHEMBL7940328 0.83 BACE1 (0.65) BACE1SMN1; SMN2ALDH1A1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2011-09-29 US disclosed
WO-2010047372-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY 塩野義製薬株式会社 (JP) 2010-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY BACE1, APP, BACE2 BACE1 1/4885SMN1; SMN2 576/4885ALDH1A1 1101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.